Hepatocellular Carcinoma
Conditions
Interventions
Treatment group:Ablation treatment for patients with hepatocellular carcinoma with the guidance of GPS magnetic navigation
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ? The maximum diameter of the tumor is 3-5cm and the number of lesions is less than 3; ? Age= 18 years old; ? HCC with clinical diagnosis or pathological diagnosis in accordance with the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer; ? The general condition of the patient was good, the physical status score (PS) was 0-1, and without obvious organic lesions of the heart, lungs, kidneys and other important organs; ? Liver function belongs to Child-Pugh class A or B; ? No extrahepatic metastasis and vascular invasion.
Exclusion criteria
Exclusion criteria: 1) Patients with other uncured malignancies in the past (within 5 years) or at the same time;2) Aminotransferase (AST or ALT) > 5 times the normal value and/or the total bilirubin is significantly elevated >3 times the normal value;3) Patients with severe infection, fever, bleeding tendency, refractory ascites effusion, and stage III and IV hepatic encephalopathy;4) Severe heart, lung, and kidney diseases, cerebrovascular accidents, Patients with severe diabetic complications, 5) pregnant or lactating patients, patients with mental disorders, 6) allergies, or known allergies to contrast agents and antibiotics, 7) those who are participating in clinical trials of other drugs or receiving other traditional Chinese medicine treatments, 8) Those who are using systemic therapy, 9) Those who are considered by the investigator to be unsuitable for clinical trials for other reasons (such as those with active alcoholic cirrhosis or autoimmune liver disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate;Changes in serum tumor markers;safety assessment; | — |
Countries
China
Contacts
Public ContactLiu Lingxiao
Zhongshan Hospital, Fudan University
Outcome results
None listed